Cancer Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Type (Chimeric Antibodies, Humanized Antibodies), By Application (Blood Cancer, Breast Cancer, Lung Cancer), By End-user- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Cancer Monoclonal Antibodies market size was estimated at USD 62.4 billion in 2021 and is expected to surpass around USD 160.7 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 11.9% during the forecast period 2022 to 2030.

Key Takeaways:

  • By Type, the U.S. Cancer Monoclonal Antibodies market was valued at USD 21.4 Billion in 2021 and expected to witness growth at a CAGR of 9.7% from 2022 to 2030.
  • By type, the humanized segment held a larger share of the market in 2021 owing to factors such as, low cost, availability, and quick production time for mouse monoclonal antibodies. However, the human segment is expected to hold the highest CAGR during the forecast period due to an increase in the number of product approvals and product launches
  • The blood cancer application segment held a significant revenue share in 2021 owing to an increase in the prevalence of hematological disorders along with a robust pipeline. In addition, the lung cancer segment is poised to expand at the highest CAGR during the forecast period
  • In 2021, the hospital segment was the leading end-user segment due to an upsurge in the number of patient hospitalizations. In addition, the availability of innovative drug therapies in the facility drives the patient preference
  • North America dominated the global market in 2021, due to the strategic activities of key market players, increasing cancer cases, and supportive government efforts in this region
  • In Asia Pacific, the market is expected to grow considerably in the future due to the increasing number of international and national collaborations among entities, especially those in developed and developing countries

Monoclonal antibody-based immunotherapy is a major element of cancer therapy besides surgery, chemotherapy, and radiation. mAbs have been recognized as one of the utmost successful therapeutic approaches for both solid tumors and hematologic malignancies in the last 20 years. The rising prevalence of cancer and increasing drug approvals along with a robust pipeline are the key factors augmenting the market growth. Millions of people globally stand to benefit both from the current monoclonal antibody-based therapies and those that are in development.

Moreover, mAbs have reduced side effects on the patient’s body when compared to chemotherapy. Furthermore, the growing adoption of cost-efficient biosimilar mAbs by oncologists and medical practitioners will further provide a boost to the growth of the market during the forecast period. In March 2020, the WHO designated COVID-19 as a pandemic. This outbreak has considerably affected both the world and the U.S. markets. In response to the COVID-19 outbreak, governments of many cities, counties, states, and other geographic regions have taken protective or preventative actions, such as imposing restrictions. As COVID-19 reached a tipping point in the U.S. and Europe during the last two weeks of March 2020, its far-reaching consequences were observed across industries and businesses, with hospitals postponing or canceling treatment procedures for cancer and halting clinical trials.

Moreover, the reduced access to health care systems to contain the pandemic resulted in a sharp decline in cancer screening. For instance, breast cancer screening saw an 87% decline in April 2020 compared to the average for the same month over the last five years. Many cancer patients had to delay or postpone their cancer treatment, which led to concerns about timely access to cancer treatments and disease recurrence or cancellation of cancer treatments. Cancer is a class of chronic diseases categorized by uncontrolled cell growth. The increasing number of cancer cases is anticipated to increase the demand for monoclonal antibodies and propel market growth.

According to the American Society of Clinical Oncology, by the end of 2022, there will be a projected 1.9 million diagnosed cancer cases and 609,360 deaths in the U.S. In addition, estimates by the same source projected that in 2020, an estimated 176,000 people globally were diagnosed with multiple myeloma. In 2022, it is projected that more than 34,000 individuals will be diagnosed with multiple myeloma, and above 12,000 people will die in the U.S. Over the past couple of years, the US FDA has approved more than a dozen monoclonal antibodies for treating various types of cancer. As scientists have discovered more antigens connected to cancer, they have been able to develop monoclonal antibodies against several cancer types.

 

In addition, clinical trials of newer monoclonal antibodies are now being carried out for various types of cancer. mAbs present a huge opportunity for the treatment of cancer due to their specificity. Their use will witness increasing demand during the forecast period, as science determines more and more novel targets in cancer cells. Many types of tumors are presently being treated with these novel biological drugs. Treatment standards involving monoclonal antibodies will continue to progress and have the probability to offer therapeutic options for cancer patients in the coming years.

Report Scope of the Cancer Monoclonal Antibodies Market

Report Coverage

Details

Market Size

US$ 160.7 Billion by 2030

Growth Rate

CAGR of 11.9% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

 Type, application, end-user,  and Region,

Companies Mentioned

F. Hoffmann-La Roche Ltd.; Bristol Myers Squibb Co.; Merck & Co.; GlaxoSmithKline plc; Johnson & Johnson; Amgen, Inc.; Novartis AG; AstraZeneca plc; Eli Lilly and Company; AbbVie

 

Type Insights

The humanized segment held the highest market share of 39.7% in 2021. Humanized monoclonal antibodies are engineered to replace the mouse-related immunogenic or epitope structures. Due to the low cost, availability, and quick production time for mouse monoclonal antibodies, the humanization of mouse monoclonal antibodies has been applied on a large scale, thereby driving the growth of the market. In addition, 50% of newly approved mAbs are humanized monoclonal antibodies.

Furthermore, innovative genetic engineering technology engaged in its production is another potential growth driver for this segment. Several humanized antibodies have now been constructed and designed, and many are at present being evaluated in clinical trials. However, the human segment is expected to be the fastest growing during the forecast period. An increase in the number of product approvals and product launches of human mAbs will positively impact the growth of the segment during the assessment years.

Application Insights

The blood cancer segment held the highest market share of 23.6% in 2021. There has been a tremendous increase in demand for hematological disorder treatments over the last three years, which has led pharmaceutical industries to develop novel medications, including cancer monoclonal antibodies. For instance, in August 2020, the FDA approved GSK’s BLENREP for treating patients with refractory or relapsed multiple myeloma.

However, lung cancer is expected to be the fastest-growing segment during the forecast period with the highest CAGR. The increasing prevalence of lung cancer will drive the product demand in near future. NSCLC is the most common type of lung cancer, and it accounts for about 85% of all lung cancer cases, with more than 2 million new cases in 2020 globally. Moreover, to cater growing burden of the disease, significant market players are implementing developmental activities that will offer growth opportunities in the near future. For instance, in June 2022, FDA accepted the application for Merck’s KEYTRUDA as an Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer after the completion of surgical resection.

End-user Insights

The hospitals segment held the highest revenue share of 39.9% in 2021. Some of the factors that can be attributed to the segmental share include the rising prevalence of cancer along with an upsurge in the number of patient hospitalizations. In addition, the availability of innovative drug therapies in hospitals drives patient preference. Furthermore, skilled professionals offering specialty treatments will drive the product demand in the hospitals.

Additionally, strategic activities by research organizations are going to generate lucrative growth opportunities during the review period. For instance, IRBM signed an agreement with The University of Texas MD Anderson Cancer Center in 2019. The contract focuses on the development of therapeutic mAbs against novel immune checkpoint targets. Similarly, in 2021, Celltrion Healthcare signed an agreement with the Brazilian Ministry of Health to supply two of its anticancer therapeutics - Truxima and Herzuma - to the market.

Regional Insights

North America dominated the cancer monoclonal antibodies market with a share of 37.8% in 2021. Strategic activities are key factors influencing the market growth. For instance, in September 2020, AbbVie and I-Mab signed a broad, international partnership agreement for the commercialization and development of lemzoparlimab, an advanced anti-CD47 monoclonal antibody discovered and developed by I-Mab for multiple cancers treatment. The partnership also allows for future collaboration on CD47-associated therapeutic agents.

Asia Pacific is estimated to be the fastest-growing region owing to increasing efforts by global firms to penetrate this emerging market to capture a higher share. An increasing number of international and national collaborations among entities, especially those in developed and developing countries, is expected to propel the market. In addition, an increase in the adoption of biosimilars in the region will further offer lucrative opportunities in the review period. For instance, in recent years, China’s biosimilar drug industry has established rapidly. By the end of 2019, the country had the maximum number of biosimilar drugs in research, with 391 biosimilar drugs in the research and development pipeline. As of December 2020, 11 biosimilar drugs had been accepted for marketing in China, comprising 6 drugs for oncology

Some of the prominent players in the Cancer Monoclonal Antibodies Market include:

  • F. Hoffmann-La Roche Ltd.
  • Bristol Myers Squibb Co.
  • Merck & Co.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Amgen, Inc.
  • Novartis AG
  • AstraZeneca plc
  • Eli Lilly and Company
  • AbbVie

 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Cancer Monoclonal Antibodies market

  • Type
    • Humanized
    • Human
    • Chimeric
    • Murine
  • Application
    • Blood Cancer
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Colorectal Cancer
    • Liver Cancer
    • Others
  • End-user
    • Hospitals
    • Research Institutes
    • Others

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Points Covered in Cancer Monoclonal Antibodies Market Study:

  • Growth of Cancer Monoclonal Antibodies in 2022
  • Market Estimates and Forecasts (2017-2030)
  •  Brand Share and Market Share Analysis
  •  Key Drivers and Restraints Shaping Market Growth
  •  Segment-wise, Country-wise, and Region-wise Analysis
  •  Competition Mapping and Benchmarking
  •  Recommendation on Key Winning Strategies
  •  COVID-19 Impact on Demand for Cancer Monoclonal Antibodies and How to Navigate
  •  Key Product Innovations and Regulatory Climate
  •  Cancer Monoclonal Antibodies Consumption Analysis
  •  Cancer Monoclonal Antibodies Production Analysis
  •  Cancer Monoclonal Antibodies and Management

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Monoclonal Antibodies Market 

5.1. COVID-19 Landscape: Cancer Monoclonal Antibodies Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Monoclonal Antibodies Market, By Type

8.1. Cancer Monoclonal Antibodies Market, by Type, 2022-2030

8.1.1 Humanized

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Human

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Chimeric

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Murine

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Cancer Monoclonal Antibodies Market, By Application

9.1. Cancer Monoclonal Antibodies Market, by Application, 2022-2030

9.1.1. Blood Cancer

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Breast Cancer

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Lung Cancer

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Melanoma

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Colorectal Cancer

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.6. Liver Cancer

9.1.6.1. Market Revenue and Forecast (2017-2030)

9.1.7. Others

9.1.7.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Cancer Monoclonal Antibodies Market, By End-user 

10.1. Cancer Monoclonal Antibodies Market, by End-user, 2022-2030

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Research Institutes

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Cancer Monoclonal Antibodies Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.3. Market Revenue and Forecast, by End-user (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.5.3. Market Revenue and Forecast, by End-user (2017-2030)

Chapter 12. Company Profiles

12.1. F. Hoffmann-La Roche Ltd.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Bristol Myers Squibb Co.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Merck & Co.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. GlaxoSmithKline plc

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Johnson & Johnson

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Amgen, Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Novartis AG

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. AstraZeneca plc

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Eli Lilly and Company

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. AbbVie

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers